Tirofiban Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 2.5 mg/mL
Reference Brands: Aggrastat (USA)
Category:
Heart Disorder
Tirofiban Hydrochloride is available in Injection
and strengths such as 2.5 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tirofiban Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tirofiban Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tirofiban, marketed under the brand name Aggrastat, is a potent antiplatelet medication belonging to the class of glycoprotein IIb/IIIa inhibitors. It acts as a small-molecule inhibitor that blocks the interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa, preventing platelet aggregation and thrombus formation. Tirofiban was developed through pharmacophore-based virtual screening, making it the first drug of its kind identified using this approach.
Clinically, tirofiban is indicated to reduce the risk of thrombotic cardiovascular events, including death, myocardial infarction, or refractory ischemia requiring repeat cardiac procedures, in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). Its rapid onset of action and reversible platelet inhibition make it a valuable therapy in acute cardiac care, particularly during hospital-managed interventions such as percutaneous coronary procedures.
Tirofiban is administered intravenously under strict medical supervision in hospital settings due to its potent antiplatelet effects. Continuous monitoring is required to manage the risk of bleeding and ensure optimal therapeutic outcomes. This targeted mechanism of action allows tirofiban to provide effective cardiovascular protection while minimizing systemic complications.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing